幽门螺杆菌感染引起非消化系统疾病的研究进展

幽门螺杆菌是一种革兰氏阴性微需氧型细菌, 可引起消化性溃疡、膜相关淋巴组织淋巴瘤和萎缩性胃炎, 是胃癌的主要诱因. 但近年来, 流行病学调查和动物实验数据提示, 该菌感染与一些非消化系统疾病, 如缺铁性贫血、特发性血小板减少性紫癜、菌血症、肺炎以及类风湿性关节炎等的发生密切相关. 本文就幽门螺杆菌感染引发非消化系统疾病的新进展进行系统剖析, 以期全面展现幽门螺杆菌感染的新领域.     

Poly(ethylene glycol)‐crosslinked fullerenes for high efficient phototherapy

Poly(ethylene glycol)‐crosslinked multimeric C₆₀ was developed for use in photothermal/photodynamic therapy of malignant cells. We showed that: (i) the tumor surface temperature on KB tumor‐bearing nude mice treated with multimeric C₆₀ reached about 44 °C; (ii) this hyperthermic condition and tremendous singlet oxygen generation from multimeric C₆₀ resulted in significant tumor volume regression in KB tumor‐bearing nude mice; and (iii) multimeric C₆₀ also efficiently inhibited arthritic progress in the arthritis‐induced DBA/1 J mice model. This multimeric C₆₀ may be useful for photothermal/photodynamic cell ablation in various malignant cells. Copyright © 2012 John Wiley & Sons, Ltd.     

蒙脱石负载氧化铈纳米酶用于克罗恩肠炎治疗

通过水热法合成由临床用药蒙脱石(Montmorillonite, MMT)负载的高效纳米酶氧化铈(Cerium dioxide, CeO₂), 通过开展体内外实验, 拓展其在炎症性肠病治疗中的普适性. 结果显示, CeO₂@MMT具有良好的类超氧化物歧化酶活性及类过氧化氢酶活性, 并且在小鼠克罗恩病的治疗中体现了明显的疗效及优异的生物安全性, 为CeO₂@MMT的应用拓宽了方向.     

Application of thiophilic chromatography to deplete serum immunoglobulins in sample preparation for bidimensional electrophoresis

Serum is a typical sample for non-invasive studies in clinical research. Its proteome characterization is challenging, since requires extensive protein depletion. Methods used nowadays for removal of high-abundance proteins are expensive or show quite often a low loading capacity, which has strong repercussions on the number of samples and replicates per analysis.In order to deplete immunoglobulins (Igs) and albumin (HSA) from 1 mL serum samples, we have developed a protocol based on a combination of thiophilic chromatography, not previously used in clinical proteomics, and a HSA-specific resin. Ig/HSA-depleted samples, immunoglobulinome and albuminone were analyzed by 2-DE. Thiophilic chromatography, coupled with HSA-depletion, allows a good 2-DE resolution as well as the visualization of new spots. Moreover, it yields enough protein to evaluate technical variability and facilitate subsequent protein identification. To validate the protocol, we carried out a preliminary comparative study between triplicate Igs/HSA-depleted serum samples from healthy control individuals and recently diagnosed/untreated rheumatoid arthritis (RA) patients. RA patients showed several acute phase proteins, as well as additional serum proteins, differentially and significantly regulated.Therefore, thiophilic chromatography can be used as an efficient and economical method in 2-DE to deplete immunoglobulins from large human serum samples before a more extensive fractioning.     

TGF-��-treated antigen presenting cells suppress collagen-induced arthritis through the promotion of Th2 responses

Collagen-induced arthritis (CIA) is mediated by self-reactive CD4⁺ T cells that produce inflammatory cytokines. TGF-β₂-treated tolerogenic antigen-presenting cells (Tol-APCs) are known to induce tolerance in various autoimmune diseases. In this study, we investigated whether collagen-specific Tol-APCs could induce suppression of CIA. We observed that Tol-APCs could suppress the development and severity of CIA and delay the onset of CIA. Treatment of Tol-APCs reduced the number of IFN-γ- and IL-17-producing CD4⁺ T cells and increased IL-4- and IL-5-producing CD4⁺ T cells upon collagen antigen stimulation in vitro. The suppression of CIA conferred by Tol-APCs correlated with their ability to selectively induce IL-10 production. We also observed that treatment of Tol-APCs inhibited not only cellular immune responses but also humoral immune responses in the process of CIA. Our results suggest that in vitro-generated Tol-APCs have potential therapeutic value for the treatment of rheumatoid arthritis as well as other autoimmune diseases.     

Sensitivity and significance of disease outcome measures in inflammatory bowel disease

In inflammatory bowel disease (IBD), proxy measures of clinical outcome are often collected into summary indices of qualitative self-rated disease markers, clinical observations, and quantitative biochemical analyses. In Crohn's disease (CD), a frequently used index is the Crohn's disease activity index (DCAI). This index consists of six qualitative variables and two quantitative variables. The aim of this presentation is to illustrate the use of this index to calculate its range, to estimate errors in the index, its sensitivity, and the number of significant steps in the index. The measure of sensitivity of the summary index was analyzed for the signal-to-noise ratio (SNR), the reference change value (RCV) and the confidence interval (CI). If identical errors were assumed in patient self-rated health and clinically judged disease manifestations, such as tumours and fistulas, the majority of the variance of the index was caused by the self-rated experience of health, the number of days over which the individual variable was rated, and the prognostic multiplier of each variable.The range of the index has no upper limit, but can be estimated to 403 units, of which patient self-rating of well-being account for up to one-third of the summary index maximal score range. The median signal noise measure of index sensitivity was 18 SDs. The two disease classification limits of 150 units for moderate disease and 450 for severe disease on average cover an interval of limit ±41.5 units vs. ±60.5 units. In judgments on change in clinical outcome the RCV interval of steps of 121 units are valid. Conclusion: Both variance and range of the CDAI summary score are primarily decided by the self-rated experience of well-being. Variables on disease signs have a minor impact on the index. Rating of the two important outcome parameters: Self-experienced health and medical outcome would favourably be given in two individual scores.Presented at the 10th Conference Quality in the Spotlight, March 2005, Antwerp, Belgium.     

The preparation,characterization, structure and dissolution analysis of apremilast solvatomorphs

Apremilast (AP) {systematic name: (S )‐2‐[1‐(3‐ethoxy‐4‐methoxyphenyl)‐2‐(methylsulfonyl)ethyl]‐4‐acetamidoisoindoline‐1,3‐dione} is an inhibitor of phosphodieasterase‐4 (PDE4) and is indicated for the treatment of adult patients with active psoriatic arthritis. The ability of AP to form solvates has been investigated and three solvatomorphs of AP, namely, the AP ethyl acetate hemisolvate, C₂₂H₂₄N₂O₇S·0.5C₄H₈O₂, the AP toluene hemisolvate, C₂₂H₂₄N₂O₇S·0.5C₇H₈, and the AP dichloromethane monosolvate, C₂₂H₂₄N₂O₇S·CH₂Cl₂, were obtained. The three AP solvatomorphs were characterized by X‐ray powder diffraction, thermogravimetric analysis and differential scanning calorimetry. Single‐crystal X‐ray diffraction was used to analyze the structures, crystal symmetry, packing modes, stoichiometry and hydrogen‐bonding interactions of the solvatomorphs. In addition, dissolution analyses were performed to study the dissolution rates of different AP solvatomorph tablets in vitro and to make comparisons with commercial apremilast tablets (produced by Celgene); all three solvatomorphs showed similar dissolution rates and similar values of the similarity factor f₂ in a comparison of their dissolution profiles.     

Selective chemiluminescence method for monitoring of vitamin K homologues in rheumatoid arthritis patients

Vitamin K is a fat-soluble vitamin involved in blood coagulation and bone metabolism. The detection and monitoring of vitamin K homologues in rheumatoid arthritis (RA) patients is a challenging problem due to the smaller concentrations of vitamin K and the presence of several interfering medications. Therefore, this study aimed to develop a new highly sensitive and selective chemiluminescence (CL) method designated to quantify vitamin K homologues in plasma of RA patients including phylloquinone (PK, vitamin K₁), menaquinone-4 (MK-4, vitamin K₂) and menaquinone-7 (MK-7, vitamin K₂). The method was based on the unique photochemical properties of vitamin K homologues that were exploited for selective luminol CL reaction. The correlation coefficients of 0.998 or more were obtained in the concentration ranges of 0.1-100 ng mL⁻¹ vitamin K homologues. The detection limits were 0.03-0.1 ng mL⁻¹ in human plasma for vitamin K homologues. The developed HPLC-CL system was successfully applied for selective determination of vitamin K homologues in plasma of RA patients. The developed method may provide a useful tool for monitoring vitamin K homologues in different clinical studies such as RA, osteoporosis and hepatocellular carcinoma in which vitamin K is intervented.     

Synthesis and Crystal Structure of (7R,8S,9S,12S)-13,14-dehydro-1-(4-fluorobenzy oxy)-N-methyl-2,13-dimethoxy-12-hydroxymorphinane

The title compound (7R,8S,9S,12S)-13,14-dehydro-1-(4'-fluorobenzyloxy)-N-methyl-2,13-dimethoxy-12-hydroxymorphinane was synthesized by the reaction of O-4-bromobenzyl-sinomenine with lithium aluminum hydride. Its chemical structure was determined by Ⅹ-ray single-crystal diffraction. The crystal belongs to triclinic, space group P1 with Mr = 439.51, a=7.7236(1), b = 8.7282(1), c = 9.9342(2) A, a = 81.176(1),β= 67.43, γ= 64.577(1)°,μ = 0.76 mm<'-1>,V= 558.45(2) A<'3>, Z = 1, Dc = 1.307 mg/m<'3>, F(000) = 234 and T= 133 K.